Redeye: Calliditas Therapeutics - Blockbuster Potential

Report this content

Redeye strongly reiterates its positive stance on Calliditas, a high-quality biotech whose longer-term blockbuster potential should be highlighted this autumn by positive Phase III trial data for its key drug Nefecon. The recent sentiment-driven downturn has pushed the share into bear territory that underestimates Nefecon’s decent likelihood of launch.

Read more and download the analysis:

Start following companies at Redeye to recieve the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.